5 June 2017

            Advanced Medical Solutions Group plc

(“AMS”, the “Company” or the “Group”)

 

            Director/PDMR and PCA Shareholding

 

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), a leading developer and manufacturer of advanced products for the global surgical and advanced wound care markets, announces that it was notified on 31 May 2017 that Chris Meredith, who is a Director and PDMR, following the successful achievement of certain performance criteria, had exercised the following options from certain share incentive schemes, as outlined below. Chris Meredith, also sold Ordinary Shares of 5p each on 31 May 2017 at a share price of 277.554p per Ordinary Share in part to cover the tax payable on this exercise. 

 

As a result of these transactions Chris Meredith’s beneficial interest in the Company has increased from 1,192,508 shares to 1,384,841 shares.

 

Long Term Incentive Plan (LTIP)

 

Director	No. of LTIPs prior to exercise	LTIPs exercised	Ordinary Shares sold	Ordinary shares retained	LTIPs after exercise
Chris Meredith, Chief Executive Officer	1,078,007	445,814	271,049	174,765	632,193

 

Deferred Share Bonus Plan (DSB)

 

Director	No. of DSBs prior to exercise	DSBs exercised	Ordinary Shares sold	DSBs after exercise
Chris Meredith, Chief Executive Officer	32,686	17,568	Nil	15,118

 

Overall holding

Director	Holding prior to exercise	Number of shares exercised	Number of shares sold	Sale price (p)	Resultant holding	% of issued share capital
Chris Meredith, Chief Executive Officer	1,192,508	463,382	271,409	277.554p	1.384,841	0.65%

 

The Company further announces that it was notified on 31 May 2017 that Mary Tavener, who is a Director and PDMR, following the successful achievement of certain performance criteria, had exercised the following options from certain share incentive schemes, as outlined below. Mary Tavener, also sold Ordinary Shares of 5p each on 31 May 2017 as detailed below at a share price of 277.554p per Ordinary Share in part to cover the tax payable on this exercise.

 

As a result of these transactions Mary Tavener’s beneficial interest in the Company has increased from 1,829,813 shares to 1,890,647 shares.

 

Long Term Incentive Plan (LTIP)

 

Director	No. of LTIPs prior to exercise	LTIPs exercised	Ordinary Shares sold	Ordinary shares retained	LTIPs after exercise
Mary Tavener, Chief Financial Officer	675,961	199,319	148,423	50,896	476,642

 

Deferred Share Bonus Plan (DSB)

 

Director	No. of DSBs prior to exercise	DSBs exercised	Ordinary Shares sold	DSBs after exercise
Mary Tavener, Chief Financial Officer	19,203	9,938	Nil	9,265

 

Overall holding

Director	Holding prior to exercise	Number of shares exercised	Number of shares sold	Sale price (p)	Resultant holding	% of issued share capital
Mary Tavener, Chief Financial Officer	1,829,813	209,257	148,423	277.554p	1,890,647	0.89%

 

The Company further announces that it was notified on 31 May 2017 that Eddie Johnson, who is a Senior Manager and PDMR, had exercised 6,243 Ordinary Shares of 5p from the Deferred Share Bonus Plan and sold 9,704 shares as detailed below at a share price of 277.554p per Ordinary Share.

 

Following these transactions the beneficial ownership of Eddie Johnson is as follows:

 

Deferred Share Bonus Plan (DSB)

 

PDMR	No. of DSBs prior to exercise	DSBs exercised	Ordinary Shares sold	DSBs after exercise
Eddie Johnson	59,237	6,243	6,243	52,994

 

Overall holding

PDMR	Holding prior to exercise	Number of shares sold	Sale price (p)	Resultant holding	% of issued share capital
Eddie Johnson	52,195	3,461	277.554p	48,734	0.023%

 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1.	Details of the person discharging managerial responsibilities/person closely associated
a)	Name: Chris Meredith
2.	Reason for the notification
a)	Position/status: Director/PDMR
b)	Initial notification/Amendment: Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name:   Advanced Medical Solutions Group plc
b)	LEI: 213800HJP6OWOSZI1L74
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594
b)	Nature of the transactions: ·        Exercise of 445,814 shares from the Long Term Incentive Plan ·        Exercise of 17,568 shares from the Deferred Share Bonus Plan ·        Sale of 271,049 Ordinary Shares of 5p
c)	Price(s) and volume(s): Sale of shares: Price(s) Volume(s) £2.77554 271,049
d)	Aggregated information: (Relates to those shares sold only) Aggregated volume: 271,049 Aggregated price: £2.77554
e)	Date of the transaction: 31/05/2017
f)	Place of the transaction: London Stock Exchange, AIM Market (XLON)

 

 

 

 

1.	Details of the person discharging managerial responsibilities/person closely associated
a)	Name: Mary Tavener
2.	Reason for the notification
a)	Position/status: Director/PDMR
b)	Initial notification/Amendment: Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name:   Advanced Medical Solutions Group plc
b)	LEI: 213800HJP6OWOSZI1L74
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594
b)	Nature of the transactions: ·        Exercise of 199,319 shares from the Long Term Incentive Plan ·        Exercise of 9,938 shares from the Deferred Share Bonus Plan ·        Sale of 148,423 Ordinary Shares of 5p
c)	Price(s) and volume(s): Sale of shares: Price(s) Volume(s) £2.77554 148,423
d)	Aggregated information: (Relates to those shares sold only) Aggregated volume: 148,423 Aggregated price: £2.77554
e)	Date of the transaction: 31/05/2017
f)	Place of the transaction: London Stock Exchange, AIM Market (XLON)

 

 

 

 

 

 

 

1.	Details of the person discharging managerial responsibilities/person closely associated
a)	Name: Eddie Johnson
2.	Reason for the notification
a)	Position/status: Senior Manager/PDMR
b)	Initial notification/Amendment: Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name:   Advanced Medical Solutions Group plc
b)	LEI: 213800HJP6OWOSZI1L74
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594
b)	Nature of the transaction: ·        Exercise of 6.243 shares from the Deferred Share Bonus Plan ·        Sale of 9,704 Ordinary Shares of 5p
c)	Price(s) and volume(s): Sale of shares: Price(s) Volume(s) £2.77554 9,704
d)	Aggregated information: (Relates to those shares sold only) Aggregated volume: 9,704 Aggregated price: £2.77554
e)	Date of the transaction: 31/05/2017
f)	Place of the transaction: London Stock Exchange, AIM Market (XLON)

 

-End –

 

 

 

 

 

 

 

 

 

 

For further information, please visit www.admedsol.com or contact:

 

Advanced Medical Solutions Group plc	Tel: +44 (0) 1606 545508
Chris Meredith, Chief Executive Officer Mary Tavener, Chief Financial Officer
Consilium Strategic Communications	Tel: +44 (0) 20 3709 5700
Mary-Jane Elliott / Jonathan Birt / Matthew Neal / Hendrik Thys	AMS@consilium-comms.com
Investec Bank plc(NOMAD & Broker)	Tel: +44 (0) 20 7597 5970
Daniel Adams / Patrick Robb

 

About Advanced Medical Solutions Group plc – see www.admedsol.com

AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical and advanced wound care markets, focused on quality outcomes for patients and value for payors. AMS has a wide range of wound care products that include silver alginates, alginates, foams, tissue adhesives, sutures and haemostats, which it sells under white label as well as its own brand ActivHeal^®, and surgical tissue adhesives, sutures and haemostats, which markets under its own brands; LiquiBand^® and RESORBA^®.

AMS’s products, manufactured out of two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic, are sold in more than 70 countries via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic and Russia.  Established in 1991, the Company has 600 employees.  For more information, please see www.admedsol.com.